Researchers reported in npj Parkinson’s Disease that selectively degrading alpha-synuclein can block preformed fibril (PFF)-induced aggregation. The study positions targeted protein degradation as a way to interfere earlier in the aggregation cascade that contributes to neurodegeneration. By focusing on degradation rather than inhibition, the approach aims to reduce available alpha-synuclein substrate that seeds misfolding. This adds to an expanding strategy set in Parkinson’s disease drug development. While still preclinical or mechanistic, the result supports continued investment in targeted degradation platforms for neurodegenerative targets where accumulation is central to pathology.